A Study of Viracept in HIV-Positive Women

Agouron Pharmaceuticals

Overview

The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

HIV Infections

Interventions

Nelfinavir mesylateDRUG

Eligibility

Sex: FEMALEMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV infection. * CD4 T cell count \<= 400 cells/mm3. Exclusion Criteria Prior Medication: Excluded: * Prior therapy or less than 1 month of therapy with d4T and/or 3TC. * Prior protease inhibitor therapy.

Locations (4)

Univ of Alabama at Birmingham

Birmingham, Alabama, United States

Univ of Southern California / LA County USC Med Cntr

Los Angeles, California, United States

HIV Outpatient Clinics / LA State Univ Med Ctr

New Orleans, Louisiana, United States

Baylor Univ

Houston, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.